Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Hexvix marketing application for bladder cancer diagnosis authorized in Europe
December 28th, 2004
PhotoCure ASA announced that its European marketing authorization application for Hexvix for diagnosis of bladder cancer has been validated and found fileable in the European Mutual Recognition procedure in 26 EU/EEA countries. The procedure started immidiately, and each country has committed to take a decision to recognize the already approved Swedish application within 90 days. National marketing authorization in each country will be issued following the approval of the Hexvix product information for doctors and patients in the local language. Vidar Hansson, PhotoCure's president and CEO, comments, "We are pleased that Hexvix now has reached the...
Source: Cancer Weekly (2004-12-28)
|
